Literature DB >> 28476790

Up-regulation of SLC9A9 Promotes Cancer Progression and Is Involved in Poor Prognosis in Colorectal Cancer.

Masami Ueda1,2, Tomohiro Iguchi1, Takaaki Masuda1, Hisateru Komatsu1,2, Sho Nambara1, Shotaro Sakimura1, Hidenari Hirata1, Ryutaro Uchi1, Hidetoshi Eguchi1, Shuhei Ito1, Keishi Sugimachi1,3, Tsunekazu Mizushima2, Yuichiro Doki2, Masaki Mori2, Koshi Mimori4.   

Abstract

BACKGROUND/AIM: SLC9A9 plays an oncogenic role in esophageal squamous carcinoma and glioblastoma. Herein, we showed an oncogenic function of SLC9A9 in colorectal cancer (CRC).
MATERIALS AND METHODS: We examined SLC9A9 expression in CRC specimens by immunohistochemistry. In CRC tissues, the relationship between SLC9A9 expression and clinicopathological factors was further elucidated by quantitative real-time polymerase chain reaction (qRT-PCR) and gene set enrichment analysis (GSEA). In vitro, we performed knockdown and overexpression experiments.
RESULTS: SLC9A9 was overexpressed in CRC specimens. In clinicopathological analysis of our cohort, high SLC9A9 expression increased liver metastasis and was correlated with worse prognoses in two cohorts. A significantly positive relationship between SLC9A9 and EGFR was revealed. While knockdown of SLC9A9 suppressed proliferation and anchorage-independent growth, up-regulation of SLC9A9 promoted proliferation and anchorage-independent growth in vitro.
CONCLUSION: SLC9A9 has an oncogenic function by being related to EGFR signaling, suggesting SLC9A9 may be a novel prognostic indicator and a therapeutic target in CRC. Copyright
© 2017, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Entities:  

Keywords:  EGFR; SLC9A9; colorectal cancer; prognosis

Mesh:

Substances:

Year:  2017        PMID: 28476790     DOI: 10.21873/anticanres.11562

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  6 in total

Review 1.  Emerging links between endosomal pH and cancer.

Authors:  Myungjun Ko; Alfredo Quiñones-Hinojosa; Rajini Rao
Journal:  Cancer Metastasis Rev       Date:  2020-06       Impact factor: 9.264

2.  The c-MYC/NAMPT/SIRT1 feedback loop is activated in early classical and serrated route colorectal cancer and represents a therapeutic target.

Authors:  Lydia Brandl; Nina Kirstein; Jens Neumann; Andrea Sendelhofert; Michael Vieth; Thomas Kirchner; Antje Menssen
Journal:  Med Oncol       Date:  2018-11-20       Impact factor: 3.064

Review 3.  (Patho-)Physiology of Na+/H+ Exchangers (NHEs) in the Digestive System.

Authors:  Li Cao; Zhenglin Yuan; Mei Liu; Christian Stock
Journal:  Front Physiol       Date:  2020-01-15       Impact factor: 4.566

4.  Integrative gene network and functional analyses identify a prognostically relevant key regulator of metastasis in Ewing sarcoma.

Authors:  Maximilian M L Knott; Thomas G P Grünewald; Florencia Cidre-Aranaz; Jing Li; Tilman L B Hölting; Martin F Orth; Roland Imle; Stefanie Kutschmann; Giulia Ammirati; Katharina Ceranski; Martha Julia Carreño-Gonzalez; Merve Kasan; Aruna Marchetto; Cornelius M Funk; Felix Bestvater; Simone Bersini; Chiara Arrigoni; Matteo Moretti; Uwe Thiel; Daniel Baumhoer; Felix Sahm; Stefan M Pfister; Wolfgang Hartmann; Uta Dirksen; Laura Romero-Pérez; Ana Banito; Shunya Ohmura; Julian Musa; Thomas Kirchner
Journal:  Mol Cancer       Date:  2022-01-03       Impact factor: 27.401

5.  Na+/H+-Exchanger Family as Novel Prognostic Biomarkers in Colorectal Cancer.

Authors:  Xin Zhou; Manman Jiang; Zhihong Liu; Mengmeng Xu; Nannan Chen; Ziyu Wu; Changji Gu; Eugene Chin; Xiaodong Yang
Journal:  J Oncol       Date:  2021-11-01       Impact factor: 4.375

6.  Structure and elevator mechanism of the mammalian sodium/proton exchanger NHE9.

Authors:  Iven Winklemann; Rei Matsuoka; Pascal F Meier; Denis Shutin; Chenou Zhang; Laura Orellana; Ricky Sexton; Michael Landreh; Carol V Robinson; Oliver Beckstein; David Drew
Journal:  EMBO J       Date:  2020-10-29       Impact factor: 14.012

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.